Download PDF
Kardiologie up2date 2011; 7(2): 102-108
DOI: 10.1055/s-0030-1256535
Hotline – Herzrhythmusstörungen

© Georg Thieme Verlag KG Stuttgart · New York

Upstream-Therapie bei Vorhofflimmern

Andreas  Goette
Further Information

Publication History

Publication Date:
21 July 2011 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

In the recent years a tremendous amount has been learned about the pathophysiology of atrial fibrillation (AF). AF induces substantial electrophysiological changes in the atrium causing electrical as well as structural changes named remodelling. Besides calcium-dependant tissue alterations, which are induced by activation of proteases and phosphatases like calpain and calciurin concomitant cardiac diseases like hypertension, heart failure and valve diseases have been demonstrated to activate the atrial angiotensin II-system. Angiotensin-II has been shown to induce progressive proarrhythmic atrial fibrosis. Initially, experimental studies suggested that therapy with angiotensin II-receptor blockers can reduce the amount of proarrhythmic fibrosis. Clinical studies, however, have provided mixed results. Especially in the last year multiple studies have been shown that the use of angiotensin II-receptor blockers does not influence the recurrence of AF. Preliminary results of the ANTIPAF trial show that a therapy with an ARB does not influence the overall burden of AF using transtelephonic ECG-monitoring.

Literatur

  • 1 Go A S, Hylek E M, Phillips K A et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.  JAMA. 2001;  285 2370-2375
    CrossrefPubMedGoogle Scholar
  • 2 Schnabel R B, Sullivan L M, Levy D et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.  Lancet. 2009;  373 739-745
    CrossrefPubMedGoogle Scholar
  • 3 Benjamin E J, Levy D, Vaziri S M et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study.  JAMA. 1994;  271 840-844
    CrossrefPubMedGoogle Scholar
  • 4 Miyasaka Y, Barnes M E, Gersh B J et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.  Circulation. 2006;  114 119-125
    CrossrefPubMedGoogle Scholar
  • 5 Naccarelli G V, Varker H, Lin J, Schulman K L. Increasing prevalence of atrial fibrillation and flutter in the United States.  Am J Cardiol. 2009;  104 1534-1539
    CrossrefPubMedGoogle Scholar
  • 6 Heeringa J, van der Kuip D A, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.  Eur Heart J. 2006;  27 949-953
    CrossrefPubMedGoogle Scholar
  • 7 Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal.  Physiol Rev. 2011;  91 265-325
    CrossrefPubMedGoogle Scholar
  • 8 Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms.  Europace. 2008;  10 238-241
    CrossrefPubMedGoogle Scholar
  • 9 Savelieva I, Kakouros N, Kourliouros A, Camm A J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.  Europace. 2011;  13 610-625
    CrossrefPubMedGoogle Scholar
  • 10 Goette A, Staack T, Röcken C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.  J Am Coll Cardiol. 2000;  35 1669-1677
    CrossrefPubMedGoogle Scholar
  • 11 Li D, Shinagawa K, Pang L et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.  Circulation. 2001;  104 2608-2614
    CrossrefPubMedGoogle Scholar
  • 12 Kumagai K, Nakashima H, Urata H et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.  J Am Coll Cardiol. 2003;  41 2197-2204
    CrossrefPubMedGoogle Scholar
  • 13 Anne W, Willems R, Roskams T et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation.  Cardiovasc Res. 2005;  67 655-666
    CrossrefPubMedGoogle Scholar
  • 14 Goette A, Bukowska A, Lendeckel U et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.  Circulation. 2008;  117 732-742
    CrossrefPubMedGoogle Scholar
  • 15 Pedersen O D, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.  Circulation. 1999;  100 376-380
    CrossrefPubMedGoogle Scholar
  • 16 Vermes E, Tardif J C, Bourassa M G et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.  Circulation. 2003;  107 2926-2931
    CrossrefPubMedGoogle Scholar
  • 17 Maggioni A P, Latini R, Carson P E et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).  Am Heart J. 2005;  149 548-557
    CrossrefPubMedGoogle Scholar
  • 18 Ducharme A, Swedberg K, Pfeffer M A et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.  Am Heart J. 2006;  152 86-92
    CrossrefPubMedGoogle Scholar
  • 19 Healey J S, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.  J Am Coll Cardiol. 2005;  45 1832-1839
    CrossrefPubMedGoogle Scholar
  • 20 Anand K, Mooss A N, Hee T T, Mohiuddin S M. Meta-analysis: inhibition of renin-Angiotensin system prevents new-onset atrial fibrillation.  Am Heart J. 2006;  152 217-222
    CrossrefPubMedGoogle Scholar
  • 21 Schneider M P, Hua T A, Böhm M et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis.  J Am Coll Cardiol. 2010;  55 2299-2307
    CrossrefPubMedGoogle Scholar
  • 22 Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.  J Am Coll Cardiol. 2005;  45 705-711
    CrossrefPubMedGoogle Scholar
  • 23 Haywood L J, Ford C E, Crow R S et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).  J Am Coll Cardiol. 2009;  54 2023-2031
    CrossrefPubMedGoogle Scholar
  • 24 Wachtell K, Gerdts E, Aurigemma G P et al. In treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the LIFE study.  Blood Press. 2010;  19 169-175
    CrossrefPubMedGoogle Scholar
  • 25 Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.  J Am Coll Cardiol. 2005;  45 712-719
    CrossrefPubMedGoogle Scholar
  • 26 Yin Y, Dalal D, Liu Z et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.  Eur Heart J. 2006;  27 1841-1846
    CrossrefPubMedGoogle Scholar
  • 27 Fogari R, Derosa G, Ferrari I et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.  Am J Hypertens. 2008;  21 1034-1039
    CrossrefPubMedGoogle Scholar
  • 28 Disertori M, Latinit R, Barlera S et al. Valsartan for prevention of recurrent atrial fibrillation.  N Engl J Med. 2009;  360 1606-1617
    CrossrefPubMedGoogle Scholar
  • 29 Camm A J, Kirchhof P, Lip G Y et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).  Europace. 2010;  12 1360-1420
    CrossrefPubMedGoogle Scholar
  • 30 Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.  Naunyn Schmiedebergs Arch Pharmacol. 2010;  381 1-13
    PubMedGoogle Scholar
  • 31 Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. The effect of simvastatin and antioxidant vitamins on atrial fibrillation—promotion by atrial tachycardia remodeling in dogs.  Circulation. 2004;  110 2313-2319
    CrossrefPubMedGoogle Scholar
  • 32 Fauchier L, Pierre B, de Labriolle A et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.  J Am Coll Cardiol. 2008;  51 828-835
    CrossrefPubMedGoogle Scholar
  • 33 Marin F, Pascual D A, Roldan V et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting.  Am J Cardiol. 2006;  97 55-60
    CrossrefPubMedGoogle Scholar
  • 34 Patti G, Chello M, Candura D et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardia Dysrhythmia After cardiac surgery) study.  Circulation. 2006;  114 1455-1461
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Andreas Goette

Chefarzt der Medizinischen Klinik II
St. Vincenz-Krankenhaus Paderborn GmbH

Am Busdorf 2
33098 Paderborn

Email: andreas.goette@vincenz.de

      >